Twelve studies were included in the review: nine randomised trials (n=2,603) and three single-group studies (n=113).
In four studies carvedilol significantly improved the lipid profile independently and in three studies there was a non-significant neutral effect. In three of the four studies that compared carvedilol with other hypertensive medications, the other drugs worsened the lipid profile significantly; carvedilol significantly improved the lipid profile in the other study.